期刊文献+

Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes

下载PDF
导出
摘要 Alzheimer's disease(AD)and type 2 diabetes(T2D):More than 55 million people suffer from dementia,and it is expected that over 150 million people will suffer from this disease by 2050.AD is the most common type of dementia and while aging remains the main risk factor to suffer it,previous studies have also shown that metabolic disorders,and T2D specifically,are also major contributors(Wang et al.,2012).
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2024年第6期1189-1190,共2页 中国神经再生研究(英文版)
基金 supported by Spanish Ministry of Science,Innovation and Universities(grant number PID2020-115499RB-I00/AEI/10.13039/501100011033) Andalusian Consejería de Universidad,Investigación e Innovación(PAIDI2020)(grant P20-00928)(to MGA)。
关键词 ALZHEIMER DIABETES
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部